Trial Profile
Evaluation of safety and efficacy of Daclizumab in multiple sclerosis patients in a real world setting
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 30 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis